ReviewHeart failure reviews2010
STEMI and heart failure in the elderly: role of adverse remodeling.
Review in Heart failure reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Pre-PCI SGLT2 inhibitors and contrast-induced nephropathy in acute myocardial infarction: A meta-analysis.Medicine · 2025Pooled it
- Clinical benefits of evolocumab in diabetic patients with STEMI undergoing PCI: a retrospective study.American journal of translational research · 2025Article
- Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry.Pharmacological research · 2023Article
- Global myocardial strain assessment by different imaging modalities to predict outcomes after ST-elevation myocardial infarction: A systematic review.World journal of cardiology · 2015Article
- Searching for the key to improve infarcted cardiac wall motion and prevent ventricular remodeling after ST-segment elevation myocardial infarction: Beyond symptom-onset-to-balloon time.Anatolian journal of cardiology · 2015Article
- AICAR-dependent AMPK activation improves scar formation in the aged heart in a murine model of reperfused myocardial infarction.Journal of molecular and cellular cardiology · 2013Article
- Heart failure in elderly patients: distinctive features and unresolved issues.European journal of heart failure · 2013Review
- The continuing saga of aging and heart failure.Heart failure reviews · 2012Article
- Role of ACE2 in diastolic and systolic heart failure.Heart failure reviews · 2012Review
- Atrial fibrillation and heart failure in the elderly.Heart failure reviews · 2012Review
- Prevention of heart failure in the elderly: when, where and how to begin?Heart failure reviews · 2012Review
- Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.Clinical interventions in aging · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The elderly population (age > or = 65 years) has been increasing worldwide. In North America and Europe, both heart failure (HF) and ST-segment elevation MI (STEMI) are more prevalent in the elderly. Morbidity, hospitalizations and costs associated with HF are higher in the elderly. Despite improved therapies, the bulk of cardiovascular deaths occur in the elderly. Survivors of acute STEMI develop progressive ventricular remodeling that leads to HF. There are several reasons for the increased HF burden in the elderly. First, there is a lack of clinical trial data exclusively in elderly patients for specific therapy of adverse remodeling post-STEMI and HF with low ejection fraction (HF/low-EF) or HF with preserved ejection fraction (HF/PEF). Second, there is the lack of data on the impact of aging on remodeling during healing post-STEMI and HF. Third, HF therapy in the elderly is more challenging because of aging-specific biological changes and associated comorbidities and polypharmacy. More research on aging and post-STEMI remodeling and clinical trials on post-STEMI remodeling and HF in the elderly are needed, especially in the "older-elderly" population segment aged > or =75 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.